Building an Innovation Foundation for 2030 and Beyond Through Partnerships and the Integration of R&D Assets
First written in FY2018. 5 of 12 entries say "Advanced", first in FY2019. Latest entry: FY2025.
72 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In 2025, Taiho Pharmaceutical entered into a joint research agreement with the Cancer Institute of the Japanese Foundation for Cancer Research and NEC Corporation to create novel cancer therapeutic vaccines using whole-genome information.」
Joint research on novel cancer therapeutic vaccines using whole-genome information was launched through collaboration with external research institutions and companies. - FY2025-H1AdvancedAnnual report
「ASTX029 ― ― United States Solid tumors Out-licensed to Mosaic Therapeutics for strategic development reasons ASTX295 ― ― United States Solid tumors Out-licensed to Mosaic Therapeutics for strategic development reasons TAS1440 ― ― United States Acute myeloid leukemia Out-licensed to Benz Sciences for strategic development reasons」
The out-licensing of R&D assets to Mosaic Therapeutics and Benz Sciences is described specifically. - FY2023SoftenedAnnual report
「Under the amended agreement, SEP-4199 and SEP-378614 were removed from the licensed compounds among the 4 compounds originally covered. Otsuka Pharmaceutical Co., Ltd. obtained from SMPA the exclusive worldwide rights to develop, manufacture and commercialize "Ulotaront" and SEP-380135 for all indications.」
The partnership with Sumitomo Pharma Co.,Ltd. changed from an agreement covering 4 compounds to one covering 2 compounds, focused on ulotaront and SEP-380135. - FY2023-Q3Deterioration in the progress of partnered development productsAnnual report
「In the healthcare business, following the failure of both the DIAMOND 1 and DIAMOND 2 studies, Phase III studies in patients with acute schizophrenia, to meet their primary endpoints for ulotaront, an intangible asset (in-process R&D) recognized mainly under the licensing agreement with Sumitomo Pharma Co.,Ltd. for joint development and commercialization was revalued because the delay in the expected timing of the regulatory application became certain. The carrying amount was reduced to its recoverable amount, which was its value in use, and an impairment loss of ¥23,106 million was recognized.」
For ulotaront under the joint development and commercialization agreement with Sumitomo Pharma Co.,Ltd., the Phase III study failed to meet its primary endpoint and the regulatory application was delayed, resulting in recognition of an impairment loss of ¥23,106 million. - FY2023-Q2RestatedAnnual report
「R&D expenses amounted to ¥142,103 million, up 13.5% year on year. The main factors behind the increase were development costs under the license agreement with Sumitomo Pharma Co.,Ltd. covering the co-development and commercialization of an antipsychotic with a novel mechanism of action as part of efforts to pursue new treatment possibilities, the steady progress of zipalertinib/TAS6417, which is being developed for non-small cell lung cancer, and sibeprenlimab/VIS649, which is being developed for IgA nephropathy, and the impact of foreign exchange rates.」
Development continues on an antipsychotic with a novel mechanism of action under the joint development and commercialization agreement with Sumitomo Pharma Co.,Ltd., as well as on zipalertinib/TAS6417 and sibeprenlimab/VIS649. - FY2022RestatedAnnual report
「In addition, we will work to strengthen our drug discovery platform and diversify drug discovery modalities through alliances, open innovation, collaboration with venture capital firms and other initiatives, with the aim of achieving sustainable evolution and growth.」
We continue to strengthen the drug discovery platform and diversify drug discovery modalities through external partnerships, open innovation and collaboration with venture capital firms. - FY2022-Q3RestatedAnnual report
「R&D expenses were ¥193,765 million, up 19.2% year on year. The main factors behind the increase were higher development expenses and other costs under the licensing agreement between Sumitomo Pharma Co.,Ltd. and Sunovion Pharmaceuticals Inc. for the joint development and commercialization of an antipsychotic with a novel mechanism of action, as well as the impact of foreign exchange rates.」
R&D for the joint development and commercialization of an antipsychotic with a novel mechanism of action under an external partnership is ongoing. - FY2022-Q1RestatedAnnual report
「In addition, development expenses based on the licensing agreement between Sumitomo Pharma Co.,Ltd. and Sunovion Pharmaceuticals Inc. for the joint development and commercialization of an antipsychotic with a novel mechanism of action」
R&D under the joint development and commercialization agreement with Sumitomo Pharma and Sunovion Pharmaceuticals Inc. for an antipsychotic with a novel mechanism of action is ongoing. - FY2021AdvancedAnnual report
「In September 2021, Dainippon Sumitomo Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. entered into a worldwide licensing agreement for the joint development and commercialization of 4 new drug candidate compounds under development in the neuropsychiatric field.」
A worldwide joint development and commercialization agreement was entered into for 4 new drug candidate compounds in the neuropsychiatric field, and an upfront payment of US$270 million was recognized. - FY2021-Q3AdvancedAnnual report
「In September 2021, Dainippon Sumitomo Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. entered into a worldwide licensing agreement for the joint development and commercialization of 4 new drug candidate compounds under development in the neuropsychiatric field.」
Dainippon Sumitomo Pharma and Sunovion Pharmaceuticals Inc. entered into a worldwide joint development and commercialization agreement for 4 new drug candidate compounds in the neuropsychiatric field. The agreement states that an upfront payment of US$270 million was recognized and that development milestone payments of US$620 million and sales milestone payments may be made. - FY2019AdvancedAnnual report
「Taiho Pharmaceutical Co., Ltd. and Astex Therapeutics Ltd. entered into an exclusive global research collaboration and licensing agreement in December 2019 with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (MSD outside the United States and Canada), specializing in small-molecule inhibitors under development for multiple drug targets, including the KRAS cancer gene.」
Specific research collaborations and licensing agreements with external companies expanded the drug discovery platform for multiple targets, including the KRAS cancer gene. - FY2018First statedAnnual report
「With regard to new drug discovery and therapeutic technologies, we actively promoted partnerships with other companies and external research institutions and integrated them with our own R&D assets, advancing the establishment of an innovation platform for growth from 2030 onward.」
The integration of partnerships with other companies and external research institutions with the Company's own R&D assets was described independently for the first time as a means of building an innovation platform for growth from 2030 onward.